Page 124 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $7.33
52wk Low $1.10 NRx Pharmaceuticals, Inc. NRXP $1.19
1201 Orange Street
Wilmington, DE 19801

(USD - in millions) www.nrxpharma.com
Market Cap 12.7
Enterprise 17.1
Basic Shares Out. 10.68 COMPANY OVERVIEW
Float 7.83
Institutional Holdings 6.92% Detailed Analysis:Channelchek.com
Short Interest 0.68
Avg. 90-Day Volume 0.12 NRx Pharmaceuticals is a clinical-stage biopharmaceutical company
developing therapeutics based on its NMDA platform for the treatment
of central nervous system disorders, specifically suicidal bipolar
depression, chronic pain, and PTSD. The Company is developing NRX-
EPS Data 101, an FDA-designated investigational Breakthrough Therapy for
suicidal treatment-resistant bipolar depression and chronic pain. NRx
2022 2023 2024 plans to file an NDA for Accelerated Approval for NRX-101 in patients
CQ1 N/A (1.60) (0.74) with bipolar depression and suicidality or akathisia. NRX-101
CQ2 (1.10) (1.20) (0.75) additionally has potential to act as a non-opioid treatment for chronic
pain, as well as a treatment for complicated UTI.
CQ3 (1.40) (0.70) (0.15)
CQ4 (1.60) (0.50) (0.69)
CY (6.10) (4.00) (2.84) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -1.65
ROE (ttm) NM
Debt-to-Total Cap. (mrq) NM
Fiscal Year End 31-Dec
1201 Orange SWilmington DE 19801

Key Executives
CEO: Javitt, Jonathan
CFO: Narido, Richard
COO: N/A
IR: Messere, Suzanne
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures